AI assistant
Neurogene Inc. — Director's Dealing 2014
Mar 6, 2014
33497_dirs_2014-03-06_8978c6ef-79a4-4484-a687-809cc25eef4a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AQUINOX PHARMACEUTICALS, INC (AQXP)
CIK: 0001404644
Period of Report: 2014-03-06
Reporting Person: JOHNSON & JOHNSON (10% Owner)
Reporting Person: JOHNSON & JOHNSON DEVELOPMENT CORP ET AL (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A-1 Preferred Stock | $ | Common Stock (255681) | Indirect | ||
| Series A-2 Preferred Stock | $ | Common Stock (170454) | Indirect | ||
| Series B-1 Preferred Stock | $ | Common Stock (293884) | Indirect | ||
| Series B-2 Preferred Stock | $ | Common Stock (292532) | Indirect | ||
| Series C Preferred Stock | $ | Common Stock (379543) | Indirect |
Footnotes
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
F2: Upon the closing of the Issuer's initial public offering each outstanding share of Preferred Stock will automatically convert into Common Stock, on a 1-to-1 basis, for no additional consideration. There is no expiration date applicable to the Preferred Stock.